Last reviewed · How we verify
NCT04644224
Parent and Family Oriented Support Interventions for the Facilitation of Weight Loss in African American Families
NA trial testing Educational Activity in Obesity-Related Malignant Neoplasm in 81 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2028
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 81 |
| Start date | 17 January 2019 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Educational Activity
- Educational Intervention
- Informational Intervention
- Questionnaire Administration
- Support Group Therapy
Conditions studied
- Obesity-Related Malignant Neoplasm — all drugs for Obesity-Related Malignant Neoplasm →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
Adults 10 to 65, any sex, with Obesity-Related Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study tests the effectiveness of parent and family oriented support interventions that are designed to help with weight loss among African American families. Obesity tends to run in families, thus family based interventions, with parents as main change agents have been strongly recommended. The parent and family oriented support Interventions may help facilitate weight loss among African American families.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Interventions to prevent obesity in children aged 5 to 11 years old.
Spiga F, Davies AL, Tomlinson E, Moore TH, et al · · 2024 · cited 40× · PMID 38763517 · DOI 10.1002/14651858.cd015328.pub2 -
Interventions to prevent obesity in children aged 12 to 18 years old.
Spiga F, Tomlinson E, Davies AL, Moore TH, et al · · 2024 · cited 30× · PMID 38763518 · DOI 10.1002/14651858.cd015330.pub2
Verify or expand the search:
- PubMed search for NCT04644224
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Educational Activity
Trials testing the same drug.
- NCT06391099 — Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic · NA · recruiting
- NCT06746012 — Designing a Dyad-Based mHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survi · NA · recruiting
- NCT05679349 — Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking · NA · recruiting
- NCT06666192 — The Ohio State University (OSU) SCREEN Community Program · NA · recruiting
- NCT05831540 — Clinical Decision Support Tools to Increase Human Papillomavirus (HPV) Vaccination in Adolescents in Pharmacies · NA · terminated
Other recruiting trials for Obesity-Related Malignant Neoplasm
Currently open trials in the same condition.
- NCT05053113 — Utilization of a Peer-Based Approach for the Promotion of Physical Activity in Inactive Women · NA · recruiting
- NCT06029517 — A Sugar-Sweetened Beverage Reduction Intervention for Native American Men · NA · active not recruiting
- NCT04447313 — Telephone Delivered Weight Loss, Nutrition, Exercise WeLNES Study · Phase 3 · active not recruiting
- NCT05094466 — Parent and Family Obesity Intervention in Reducing Obesity Risk in Racial Ethnic Minority Families · NA · active not recruiting
- NCT04611087 — Self-monitoring Focus Groups With Vibrant Lives Pasadena Participants · recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04644224 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 9 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04644224.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing